Elda Alba-Suárez

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Celia Oreja‐Guevara

Universidad Complutense de Madrid

Irene Gómez-Estévez

Hospital Clínico San Carlos

Lorena García-Vasco

Hospital Clínico San Carlos

C. I. Ramirez

Complejo Asistencial Sótero del Río

Elizabeth Martínez‐Pérez

Fundación Instituto Leloir

Irene Gómez-Estévez

Hospital Clínico San Carlos

C. Bullón-Sanchez

Javier Moarquez-Rodriguez

Judit Díaz-Díaz

Hospital Clínico San Carlos

María Beatriz Castro-Hernández

Hospital Universitario de Canarias

Cooperative Institutions

Hospital Clínico San Carlos

Instituto de Investigación Sanitaria del Hospital Clínico San Carlos

Universidad Complutense de Madrid

Universidad de Salamanca

Research Institute Hospital 12 de Octubre

Hospital Universitario Príncipe de Asturias

Complejo Asistencial Sótero del Río

Fundación Instituto Leloir

European Molecular Biology Laboratory

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

1. Impact of Menopause on Quality of Life in Multiple Sclerosis Patients

Multiple Sclerosis and Related Disorders (2024)

Celia Oreja‐Guevara Javier Moarquez-Rodriguez Lorena García-Vasco Irene Gómez-Estévez Elda Alba-Suárez

10.1016/j.msard.2024.105962

Cite

Citations (0)

COVID-19 vaccination and humoral immune response in people with multiple sclerosis

Multiple Sclerosis Journal (2021)

Celia Oreja‐Guevara C. I. Ramirez Elda Alba-Suárez Irene Gómez-Estévez C. Bullón-Sanchez

Introduction: The COVID-19 pandemic potentially affected decisions around prescribing MS disease modifying therapies (DMTs) due to concerns about the safety of their use and disruptions to healthcare services. Objectives: To depict prescribing trends of MS DMTs during the COVID-19 outbreak in England and compare it to DMT use in other countries. Aims: To understand the effect of the pandemic on prescribing MS DMTs in England compared to other countries. Methods: National Health Service (NHS) England and NHS Improvement data on all issued MS DMT prescriptions during (1/03/2020 to 31/12/2020) and before (1/05/2019 to 29/02/2020) the outbreak was analysed. Interrupted time series analysis was used to depict the effect of the outbreak in England on prescribing trends of total and individual DMTs which will be presented as diagrams. Results: The outbreak had not affected the stationary trend of total DMT prescriptions;median (interquartile range) number of prescriptions per month was 20789 (2489) before and 21102 (1824) during the outbreak. COVID-19 significantly accelerated the pre-pandemic decline of alemtuzumab prescriptions, which dropped from 219 (85) to 63 (31) per month and remained low. The upward trend of cladribine and ocrelizumab prescriptions before the outbreak was interrupted by the first wave with their nadir during the first peak (April-May 2020). The monthly prescriptions of cladribine and ocrelizumab were 249 (47) and 641 (297) before the outbreak and dropped to 18 and 191 in May 2020, respectively. During the first 10 months of the pandemic, there was a 16% reduction in the number of MS patients treated with their firstever DMT from 3847 before to 3241 during the outbreak. These changes were mostly due to significant reductions in prescription of alemtuzumab, cladribine, and ocrelizumab especially during the peaks of the first and second (November 2020) waves of the outbreak which were not compensated by other DMTs. There was an increase in monthly natalizumab prescriptions as first-ever treatment from 32 (18) before to 61 (24) during the outbreak. Conclusion: These changes reflect recommendations of published guidelines on MS DMT use. Comparison of prescribing trends of MS DMTs in England with those from other countries highlights the interplay of different factors in altering DMT prescription practices. These observations have implications in population- based studies involving MS disease activity including the period of the COVID-19 pandemic.

Pandemic

Interquartile range

Cladribine

Source

Cite

Citations (0)